Skip to main content
Fig. 3 | Cancer Cell International

Fig. 3

From: As a biomarker for gastric cancer, circPTPN22 regulates the progression of gastric cancer through the EMT pathway

Fig. 3

The diagnostic and prognostic value of circPTPN22 in GC. a The expression levels of circPTPN22 in plasma specimens of GC primary patients (n = 120), gastritis patients (n = 70), and healthy donors (n = 104). b The expression levels of circPTPN22 in plasma specimens of GC at different stages of lymph node metastasis. c, d ROC curve analysis of circPTPN22, CEA, and CA199 in independent diagnosis and joint diagnosis of GC patients and healthy donors. e, f ROC curve analysis of circPTPN22, CEA, and CA199 in independent diagnosis and joint diagnosis of GC patients and gastritis patients. g The expression levels of plasma circPTPN22 in the 20 GC patients before and after surgery. h Kaplan–Meier survival curve verifies the prognostic value of circPTPN22

Back to article page